Please login to the form below

Not currently logged in

Eucomed backs EC plans to strengthen medical devices measures

Implant registers, support for adverse event reporting and increased spot checks by Member States encouraged after PIP controversy

The European Commission's (EC) plans to strengthen its existing medical devices legislation in the wake of the PIP breast implants controversy have been backed by industry body Eucomed.

The proposed measures aim to make EC Member States tighten controls, improve the safety guarantee for medical devices and restore patient confidence in devices legislation.

PIP implants, which were withdrawn in the EU in 2010, were found to be made with low-grade silicone with an increased risk of rupturing, with weak European legislation taking some of the blame for allowing the implants to reach the market.

European Health and Consumer Policy Commissioner John Dalli has written to Member States proposing several actions including reinforcing market surveillance by increasing 'spot checks' of manufacturing facilities.

Other actions included improving the vigilance system for medical devices by encouraging healthcare professionals and patients to report adverse events as well as developing the co-ordination of analysing reported incidents.

Giving systematic access for notified bodies to reports of adverse events was also suggested, as well as supporting the development of tools - like Unique Device Identification systems and implant registers - to trace medical devices and monitor their long-term safety and performance.

These plans were announced ahead of the EC's planned revision of the medical devices legislation, scheduled for adoption in the spring, and have support from Eucomed, the European body for medical devices.

In a statement, the organisation said the EC's measures were "balanced and appropriate and will have a positive effect on patient safety".

Device legislation is still under review, however, and Eucomed offered six improvements to create what it describes as a "smarter legal framework for medical devices".

These are:

• Only the best Notified Bodies

• One approach to vigilance and market surveillance

• Strengthened harmonised standards

• Consistent implementation of guidelines

• Increased transparency

• An integrated approach: better coordination and management.

Eucomed has released a position paper, entitled 'A new EU regulatory framework for medical devices', with further information on the changes it would like to see to European legislation.

Earlier this week, former Eucomed CEO John Wilkinson joined the Medicines and Healthcare products Regulatory Agency (MHRA) as its director of medical devices in the UK, where 40,000 women are thought to have received PIP implants.

10th February 2012


COVID-19 Updates and Daily News

Featured jobs


Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...